Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study

Depression is more than a feeling of sadness; for many, it is a stubborn illness that resists standard treatments, leaving patients trapped in a cycle of hopelessness. When common medications fail, doctors sometimes turn to a different class of drugs based on ketamine, a substance originally used as an anesthetic. In recent years, a specific form of this drug, delivered as a nasal spray called esketamine, has shown promise in rapidly lifting the heavy fog of severe depression. However, the drug does not work for everyone, and scientists have long wondered why. Some researchers suspect that the body's broader health, particularly how it handles energy and sugar, might hold the key. This area of study looks at "metabolic burden," a term describing the cumulative strain on the body when systems like blood sugar, blood pressure, and waist size drift out of their healthy ranges. Understanding whether this physical strain helps or hinders the drug's ability to clear the mind is a crucial step toward personalized medicine.

A team of researchers at the University of Ottawa set out to explore this connection in a real-world clinical setting. They followed thirty individuals suffering from treatment-resistant depression who were about to undergo a standard course of eight intranasal esketamine treatments over four weeks. Before the first dose, and again after the final dose, the team measured a wide array of biological signals. They looked not just at the severity of depression, but also at the patients' metabolic health, their levels of inflammation, and their levels of neurotrophic factors, which are proteins that help brain cells grow and connect. The goal was to see if a patient's starting biological profile could predict how well they would respond to the treatment, and whether the treatment itself changed these biological markers.

The results offered a surprising twist in the story of depression treatment. The patients who started with the highest "metabolic burden"—meaning they had the most signs of metabolic syndrome, such as high blood pressure, high triglycerides, or excess waist circumference—actually saw the greatest reduction in their depressive symptoms. This finding challenges the older idea that poor metabolic health makes a person less likely to respond to psychiatric medication. In this study, the more metabolic issues a patient had at the start, the more their mood improved after the series of treatments. The researchers calculated that the average drop in depression scores was significant, and the link between metabolic burden and improvement remained strong even after accounting for how severe the depression was to begin with.

While the metabolic markers predicted who would get better, the treatment also seemed to change the body's chemistry in a specific way. After the eight treatments, the patients' fasting blood sugar levels dropped significantly. This decrease happened without any change in their body weight or how much they exercised, suggesting the drug itself may have influenced how the body processes sugar. In fact, nearly all participants saw their blood sugar go down, and for some, the levels fell so low that they technically entered a range usually associated with hypoglycemia, though they reported no symptoms of low sugar. The study also found that a measure of insulin resistance, which indicates how hard the body has to work to manage blood sugar, decreased significantly. These changes suggest that esketamine might have a direct, beneficial effect on metabolic health that goes beyond just treating the mind.

In contrast to the clear metabolic signals, the study found no such patterns in the other biological domains they examined. The researchers looked closely at markers of inflammation and neurotrophic factors, hoping to find a biological signature that predicted who would respond to the drug. They found no evidence that the starting levels of these markers could forecast the outcome. Furthermore, the treatment did not cause significant changes in these inflammatory or neurotrophic levels over the course of the study. This absence of change highlights that the metabolic system may be a more sensitive or relevant indicator for this specific treatment than the immune or nerve-growth systems.

One detail emerged when the researchers looked more closely at a specific protein called vascular endothelial growth factor, or VEGF, which helps blood vessels grow. When they removed patients with diabetes or those taking medications that alter blood sugar from the analysis, a pattern appeared: higher starting levels of VEGF were linked to greater improvements in depression. This suggests that while the broad metabolic burden was the strongest overall predictor, specific biological factors might still play a role in a subset of patients. However, because the study was relatively small, the researchers view this finding as a hint for future investigation rather than a definitive rule.

The study also addressed what the drug does not do. It did not cause patients to gain or lose weight, nor did it change their exercise habits, reinforcing that the drop in blood sugar was a direct effect of the treatment rather than a side effect of lifestyle changes. The researchers also noted that the drug did not work equally for everyone; while the average improvement was substantial, only a small fraction of patients achieved full remission, meaning their symptoms disappeared completely. The study was conducted in an open clinical setting without a placebo group, which means the researchers could not rule out the possibility that some improvement came from the patients' expectations or the care they received, though the biological changes in blood sugar point to a genuine physiological effect.

Ultimately, this research suggests that the body's metabolic state is a vital piece of the puzzle in treating severe depression. It indicates that individuals with significant metabolic issues might actually be the ones who benefit most from esketamine, turning a common health risk factor into a potential predictor of success. The discovery that the treatment lowers blood sugar independently of weight loss opens a new door for understanding how this drug works, suggesting it may be reshaping the body's energy metabolism as it lifts the mind. While more research is needed to confirm these findings and understand the long-term effects, the study provides a clear, concrete example of how looking at the whole body, not just the brain, can reveal new paths to healing.